Lead Product(s) : Afamelanotide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CLINUVEL Recruits 200 Patients in Phase III Vitiligo Trial CUV105
Details : Scenesse (afamelanotide) is a melanocortin 1 receptor (MC1-R) agonist, being investigated for the patients with vitiligo.
Product Name : Scenesse
Product Type : Peptide
Upfront Cash : Inapplicable
May 07, 2025
Lead Product(s) : Afamelanotide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable